Why are the two -metal dual -dual -double used, and the other two types of hypoglycemic drugs are used more and more?

A friend with diabetes told Huazi that he found that there were fewer and fewer people with diabetes around him, and more people were using various "peptides" injections, and various "Leein" Why is this oral medicine, is this? Is it eliminated?

Hua Zi said that the two -metal dual -dual -dual -dual -dual -dual -dual -dual -dual -dual -bearing has been found in diabetes, and people have found that two kinds of hypoglycemic drugs have a stronger protection effect on organs. In the 2022 version of "ADA/EASD: Type 2 Diabetes Hyperogenic High Globe Management Consensus (Draft)", the GLP1 receptor agonist and SGLT2 inhibitor are proposed to protect the heart and kidneys more than the two -meta.

1. Diabetes can damage the heart and the kidneys

Diabetes can cause porridge hardened by large arteries, and diabetic patients are more likely to concurrent coronary heart disease. Hyplycemia can also cause damage to the micro -blood vessels and nerves of the heart. "Waiting for crisis".

Diabetic nephropathy is also one of the main complications of diabetes. Diabetes will affect the kidney blood vessels and glomerular goals, causing nephrotid stenosis and glomerular degeneration, causing proteinuria and abnormalities. If it cannot be controlled in time, diabetic nephropathy will advance until the end -stage nephropathy, that is, uremia, which will pose a great threat to patients' lives.

Second, hypoglycemic should also protect the organs

People with diabetes are usually divided into two cases. One is a patient with new diabetes, which is generally lighter and weighs, and has no organ damage. The treatment of such people is mainly to reduce blood sugar and control weight. You can choose a two -meta dual -dual -dual -dual -dual -dual -dual -dual -dual -dual -dual -dual -dual -dual -dual -duplexing effect of blood sugar and weight.

Another situation is patients with long diabetes with a long course and older diabetes, facing a higher risk of heart and kidney injury. The focus of treatment is to reduce the risk of adverse incidents of heart and kidney while controlling blood sugar. It is recommended to treat the GLP1 receptor agonist and SGLT2 inhibitor with a stronger protective effect on the heart and kidneys for treatment without traditional dual -duplex.

3. GLP1 receptor agonist and SGLT2 inhibitor

GLP1 receptor agonist (pancreatic hypoglyce peptide-1 receptor agonist), commonly used drugs such as beneficial favors, ductame peptides, and Sigmeuti peptides to activate the GLP1 receptor through the subcutaneous injection method to activate the GLP1 receptor It can stimulate insulin secretions by glucose dependence, reducing blood sugar while suppressing appetite, and has a good heart and kidney protection.

SGLT2 inhibitors (sodium-glucose collaborative transfer protein 2 inhibitors), commonly used are Permonicon, Caglie Jing, Daglie Clean and other drugs. The SGLT2 receptor that acts on the renal tubules inhibits its heavy absorption of glucose in the raw urine, and the glucose is discharged from the urine and reduced blood sugar. It can reduce the risk of cardiovascular disease, and has potential renal protection effect on those with mild and moderate renal function.

4. Most patients with type 2 diabetes have heart and kidney risk

Type 2 diabetes is a chronic disease that cannot be cured. As the course of disease increases, most patients with type 2 diabetes will face higher heart and kidney risk. Treatment goals must not only reduce sugar, but also protect the heart and kidneys. Therefore, in the selection of medication, more diabetic patients chose the GLP1 receptor agonist and SGLT2 inhibitor.

The GLP1 receptor agonist is more biased towards cardiovascular protection, and in some countries, it has also approved the indications for weight loss; SGLT2 inhibitors have better effect on kidney protection and help prevent heart failure. If the effect of using hypoglyception alone is not satisfactory, the two can be used in combination with the binochalin and other hypoglycemic drugs.

To sum up, when treating diabetes, you must not only control blood sugar, but also pay attention to protecting the heart and kidneys. Compared with the traditional di metama, the GLP1 receptor agonist and the SGLT2 inhibitor have a stronger organ protection effect. When taking medicine, the doctor needs to be selected according to the purpose of treatment. If you have doubts about medication, please consult a doctor or pharmacist. I am a pharmacist, and welcome to follow me and share more health knowledge.

- END -